TG Therapeutics wins VA contract for Briumvi

by
Contributor since / Followers
9 months ago
Multiple Sclerosis written on black background with stethoscope.

Md Saiful Islam Khan/iStock via Getty Images

  • TG Therapeutics (NASDAQ:TGTX) announced Thursday that the U.S. Department of Veterans Affairs awarded it a national contract, listing its multiple sclerosis (MS) therapy Briumvi as a preferred therapy for the central nervous system (CNS) disorder.
  • Accordingly, Briumvi, an anti-CD20 monoclonal antibody, will be
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *